Guidelines for the preventive treatment of ischaemic stroke and TIA (II). Recommendations according to aetiological sub-type;Guía para el tratamiento preventivo del ictus isquémico y AIT (II). Recomendaciones según subtipo etiológico

Neurologia

Volumn 29, Issue 3, 2014, Pages 168-183

  Fuentes, B ^a   Gallego J ^a   Gil Nunez A ^a   Morales, A ^a   Purroy, F ^a   Roquer, J ^a   Segura, T ^a   Tejada, J ^a   Lago, A ^a   Diez Tejedor E ^a   Alonso de Lecinana M ^a   Alvarez Sabin J ^a   Arenillas, J ^a   Calleja, S ^a   Casado, I ^a   Castellanos, M ^a   Castillo, J ^a   Davalos A ^a   Diaz Otero F ^a   Egido, J A ^a   Lopez Fernandez J C ^a   Freijo, M ^a   Garcia Pastor A ^a   Gilo, F ^a   Irimia, P ^a   Maestre, J ^a   Masjuan, J ^a   Marti Fabregas J ^a   Martinez Sanchez P ^a   Martinez Vila E ^a   Molina, C ^a   Nombela, F ^a   Ribo M ^a   Rodriguez Yanez M ^a   Rubio, F ^a   Serena, J ^a   Simal, P ^a   Vivancos, J ^a   more..

^a NONE

Author keywords

Guidelines; Ischaemic stroke; Prevention; Transient ischemic attack

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CEREBRAL REVASCULARIZATION; CEREBRAL SINUS THROMBOSIS; EVIDENCE BASED MEDICINE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; PROPHYLAXIS; RECURRENT DISEASE; RISK FACTOR; SHORT SURVEY; THROMBUS; TRANSIENT ISCHEMIC ATTACK; VALVULAR HEART DISEASE; CLASSIFICATION; ISCHEMIC ATTACK, TRANSIENT; STROKE;

BRAIN ISCHEMIA; EVIDENCE-BASED MEDICINE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; STROKE;

EID: 84897410708     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: 10.1016/j.nrl.2011.06.003     Document Type: Short Survey

References (118)

1. Instituto Nacional de Estadística. Defunciones según causa de muerte 2006. [consultado 29 Jul 2011]. Disponible en: http://www.ine.es/prensa/np490.pdf.
2. Adams R.J., Chimowitz M.I., Alpert J.S., Awad I.A., Cerqueria M.D., Fayad P., et al. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Stroke 2003, 34:2310-2322.
3. Fuentes B, Gallego J, Gil-Nuñez A, Morales A, Purroy F, Roquer J, Segura T, Tejada J, Lago A, Díez-Tejedor E. Guía para el tratamiento preventivo del ictus isquémico y AIT (I). Actuación sobre los factores de riesgo y estilo de vida. Neurología.2011. doi:10.1016/j.nrl.2011.06.002%203.
4. Centre for Evidence Based Medicine. [consultado 29 Jul 2011]. Disponible en: http://www.cebm.net/.
5. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994, 308:81-106. Antiplatelet Trialists' Collaboration.
6. Algra A., van Gijn J. Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 1999, 66:255.
7. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86. Antithrombotic Trialists' Collaboration.
8. Algra A., van Gijn J. Aspirin at any dose above 30mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 1996, 60:197-199.
9. Johnson E.S., Lanes S.F., Wentworth C.E., Satterfield M.H., Abebe B.L., Dicker L.W. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med 1999, 159:1248-1253.
10. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329-1339. CAPRIE Steering Committee.
11. Ringleb P.A., Bhatt D.L., Hirsch A.T., Topol E.J., Hacke W. Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events Investigators. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004, 35:528-532.
12. Matias-Guiu J., Ferro J.M., Álvarez-Sabin J., Torres F., Jiménez M.D., Lago A., et al. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. Stroke 2003, 34:840-848.
13. Culebras A., Rotta-Escalante R., Vila J., Dominguez R., Abiusi G., Famulari A., et al. Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study. Neurology 2004, 62:1073-1080.
14. Costa J., Ferro J.M., Matias-Guiu J., Álvarez-Sabin J., Torres F. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev 2005, CD004296.
15. De Schryver E.L.L.M., Algra A., van Gujn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane database of Systematic reviews 2007, (Issue 3):CD001820.
16. Shinohara Y., Katayama Y., Uchiyama S., Yamaguchi T., Handa S., Matsuoka K., et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010, 9:959-968.
17. Kamal A.K., Naqvi I., Husain M.R., Khealani B.A. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev 2011, CD008076.
18. Shinohara Y., Nishimaru K., Sawada T., Terashi A., Handa S., Hirai S., et al. Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. Stroke 2008, 39:1827-1833.
19. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015.
20. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-1057.
21. Diener H.C., Cunha L., Forbes C., Sivenius J., Smets P., Lowenthal A. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143(1-2):1-13. European Stroke Prevention Study. 2.
22. Halkes P.H., van Gijn J., Kappelle L.J., Koudstaal P.J., Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006, 367:1665-1673. ESPRIT Study Group.
23. Verro P., Gorelick P.B., Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke 2008, 39:1358-1363.
24. Sacco R.L., Diener H.C., Yusuf S., Cotton D., Ounpuu S., Lawton W.A., et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008, 359:1238-1251.
25. Bath P.M., Cotton D., Martin R.H., Palesch Y., Yusuf S., Sacco R., et al. Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. Stroke 2010, 41:732-738.
26. Diener H.C., Sacco R.L., Yusuf S., Cotton D., Ounpuu S., Lawton W.A., et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol 2008, 7:875-884.
27. Diener H.C., Bogousslavsky J., Brass L.M., Cimminiello C., Csiba L., Kaste M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004, 364:331-337.
28. Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006, 354:1706-1717.
29. Geeganage C., Wilcox R., Bath P.M. Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis. BMC Med 2010, 8:36.
30. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997, 42:857-865. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group.
31. Mohr J.P., Thompson J.L., Lazar R.M., Levin B., Sacco R.L., Furie K.L., et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001, 345:1444-1451.
32. Halkes P.H., van Gijn J., Kappelle L.J., Koudstaal P.J., Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 2007, 6:115-124. ESPRIT Study Group.
33. Algra A., De Schryver E.L., van Gijn J., Kappelle L.J., Koudstaal P.J. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2006, 3:CD001342.
34. Chimowitz M.I., Lynn M.J., Howlett-Smith H., Stern B.J., Hertzberg V.S., Frankel M.R., et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005, 352:1305-1316.
35. Kasner S.E., Lynn M.J., Chimowitz M.I., Frankel M.R., Howlett-Smith H., Hertzberg V.S., et al. Warfarin vs aspirin for symptomatic intracranial stenosis: subgroup analyses from WASID. Neurology 2006, 67:1275-1278.
36. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991, 325:445-453. North American Symptomatic Carotid Endarterectomy Trial Collaborators.
37. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet 1991, 337:1235-1243. European Carotid Surgery Trialists' Collaborative Group.
38. Barnett H.J., Taylor D.W., Eliasziw M., Fox A.J., Ferguson G.G., Haynes R.B., et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998, 339:1415-1425.
39. Endarterectomy for moderate symptomatic carotid stenosis: interim results from the MRC European Carotid Surgery Trial. Lancet 1996; 347:1591-3.
40. Rothwell P.M., Eliasziw M., Gutnikov S.A., Warlow C.P., Barnett H.J. Carotid Endarterectomy Trialists Collaboration. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 2004, 363:915-924.
41. European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25:457-507.
42. Furie K.L., Kasner S.E., Adams R.J., Albers G.W., Bush R.L., Fagan S.C., et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011, 42:227-276.
43. Chaturvedi S., Bruno A., Feasby T., Holloway R., Benavente O., Cohen S.N., et al. Carotid endarterectomy--an evidence-based review: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2005, 65:794-801.
44. Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomised trial. Lancet 2001, 357:1729-1737.
45. Gurm H.S., Yadav J.S., Fayad P., Katzen B.T., Mishkel G.J., Bajwa T.K., et al. Long-term results of carotid stenting versus endarterectomy in high-risk patients. N Engl J Med 2008, 358:1572-1579.
46. Mas J.L., Chatellier G., Beyssen B., Branchereau A., Moulin T., Becquemin J.P., et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 2006, 355:1660-1671.
47. Ringleb P.A., Allenberg J., Bruckmann H., Eckstein H.H., Fraedrich G., et al. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 2006, 368:1239-1247. SPACE Collaborative Group.
48. Mas J.L., Trinquart L., Leys D., Albucher J.F., Rousseau H., Viguier A., et al. Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial. Lancet Neurol 2008, 7:885-892.
49. Eckstein H.H., Ringleb P., Allenberg J.R., Berger J., Fraedrich G., Hacke W., et al. Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. Lancet Neurol 2008, 7:893-902.
50. Wiesmann M., Schopf V., Jansen O., Bruckmann H. Stent-protected angioplasty versus carotid endarterectomy in patients with carotid artery stenosis: meta-analysis of randomized trial data. Eur Radiol 2008, 18:2956-2966.
51. Ederle J., Dobson J., Featherstone R.L., Bonati L.H., van der Worp H.B., et al. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. Lancet 2010, 375:985-997. International Carotid Stenting Study investigators.
52. Ederle J., Bonati L.H., Dobson J., Featherstone R.L., Gaines P.A., Beard J.D., et al. Endovascular treatment with angioplasty or stenting versus endarterectomy in patients with carotid artery stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): long-term follow-up of a randomised trial. Lancet Neurol 2009, 8:898-907.
53. Brott T.G., Hobson R.W., Howard G., Roubin G.S., Clark W.M., Brooks W., et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010, 363:11-23.
54. Stingele R., Berger J., Alfke K., Eckstein H.H., Fraedrich G., Allenberg J., et al. Clinical and angiographic risk factors for stroke and death within 30 days after carotid endarterectomy and stent-protected angioplasty: a subanalysis of the SPACE study. Lancet Neurol 2008, 7:216-222.
55. Brott T.G., Halperin J.L., Abbara S., Bacharach J.M., Barr J.D., Bush R.L., et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS AT Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American ssociation of Neuroscience Nurses,American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Stroke 2011, 42:e420-463.
56. Coward L.J., McCabe D.J., Ederle J., Featherstone R.L., Clifton A., Brown M.M. Long-term outcome after angioplasty and stenting for symptomatic vertebral artery stenosis compared with medical treatment in the Carotid And Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomized trial. Stroke 2007 May, 38:1526-1530. CAVATAS Investigators.
57. Kasner S.E., Chimowitz M.I., Lynn M.J., Howlett-Smith H., Stern B.J., Hertzberg V.S., et al. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation 2006, 113:555-563.
58. Fiorella D., Levy E.I., Turk A.S., Albuquerque F.C., Niemann D.B., Aagaard-Kienitz B., et al. US multicenter experience with the wingspan stent system for the treatment of intracranial atheromatous disease: periprocedural results. Stroke 2007, 38:881-887.
59. Kurre W., Berkefeld J., Brassel F., Bruning R., Eckert B., Kamek S., et al. In-hospital complication rates after stent treatment of 388 symptomatic intracranial stenoses: results from the INTRASTENT multicentric registry. Stroke 2010, 41:494-498.
60. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. N Engl J Med 1985, 313:1191-1200. The EC/IC Bypass Study Group.
61. Fluri F., Engelter S., Lyrer P. Extracranial-intracranial arterial bypass surgery for occlusive carotid artery disease. Cochrane Database Syst Rev 2010, CD005953.
62. Gil Nunez A. Advances in the prevention of cerebral ischaemia due to atrial fibrillation]. Neurologia 2010, 25:401-408.
63. Camm A.J., Kirchhof P., Lip G.Y., Schotten U., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010, 31:2369-2429. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery.
64. Wann L.S., Curtis A.B., January C.T., Ellenbogen K.A., Lowe J.E., Estes N.A., et al. ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 123:1144-1150.
65. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993, 342:1255-1262. EAFT (European Atrial Fibrillation Trial) Study Group.
66. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867.
67. Samsa G.P., Matchar D.B., Goldstein L.B., Bonito A.J., Lux L.J., Witter D.M., et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 2000, 160:967-973.
68. Gladstone D.J., Bui E., Fang J., Laupacis A., Lindsay M.P., Tu J.V., et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009, 40:235-240.
69. Pisters R., Lane D.A., Nieuwlaat R., de Vos C.B., Crijns H.J., Lip G.Y. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010, 138:1093-1100.
70. Singer D.E., Chang Y., Fang M.C., Borowsky L.H., Pomernacki N.K., Udaltsova N., et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009, 151:297-305.
71. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
72. Diener H.C., Connolly S.J., Ezekowitz M.D., Wallentin L., Reilly P.A., Yang S., et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010, 9:1157-1163.
73. Freeman J.V., Zhu R.P., Owens D.K., Garber A.M., Hutton D.W., Go A.S., et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011, 154:1-11.
74. Wann L.S., Curtis A.B., Ellenbogen K.A., Estes M., Ezekpwotz M.D., Jackman W.M., January C.T., Lowe J.E., Page R.L., Slotwiner D.J., Stevenson W.G., Tracy C.M. 2011 ACCF/AHA/HRS Focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of cardiology Foundation/American Heart Association Task Force on practice Guidelines. Circulation 2011, 123:104-123.
75. Connolly S.J., Eikelboom J., Joyner C., Diener H.C., Hart R., Golitsyn S., et al. Apixaban in Patients with Atrial Fibrillation. N Engl J Med 2011, 364:806-817. the AVERROES Steering Committee and Investigators.
76. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010, 159:340-347. ROCKET AF Study Investigators.
77. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W., Breithardt G., Halperin J.L., Hankey G.J., Piccini J.P., Becker R.C., Nessel C.C., Paolini J.F., Berkowitz S.D., Fox K.A., Califf R.M. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
78. Connolly S.J., Pogue J., Hart R.G., Hohnloser S.H., Pfeffer M., et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009 May 14, 360:2066-2078. ACTIVE Investigators.
79. Connolly S., Pogue J., Hart R., Pfeffer M., Hohnloser S., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006, 367:1903-1912. ACTIVE Writing Group of the ACTIVE Investigators.
80. Gorelick P.B. Combining aspirin with oral anticoagulant therapy: is this a safe and effective practice in patients with atrial fibrillation?. Stroke 2007, 38:1652-1654.
81. Perez-Gomez F., Alegria E., Berjon J., Iriarte J.A., Zumalde J., Salvador A., et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004, 44:1557-1566.
82. Bover R., Pérez-Gómez F., Maluenda M.P., Asenjo S., Pérez-Saldana R., Igea A., et al. Prospective evaluation of different antiplatelet treatments. Rev Esp Cardiol 2009, 62:992-1000. Long-term follow-up of atrial fibrillation patients in the NASPEAF study.
83. Hohnloser S.H., Crijns H.J., van Eickels M., Gaudin C., Page R.L., Torp-Pedersen C., et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009, 360:668-678.
84. Connolly S.J., Crijns H.J., Torp-Pedersen C., van Eickels M., Gaudin C., Page R.L., et al. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation 2009, 120:1174-1180.
85. Natale A., Raviele A., Arentz T., Calkins H., Chen S.A., Haissaguerre M., et al. Venice Chart international consensus document on atrial fibrillation ablation. J Cardiovasc Electrophysiol 2007, 18:560-580.
86. Bertaglia E., Tondo C., De Simone A., Zoppo F., Mantica M., Turco P., et al. Does catheter ablation cure atrial fibrillation? Single-procedure outcome of drug-refractory atrial fibrillation ablation: a 6-year multicentre experience. Europace 2010, 12:181-187.
87. Fauchier L., Pierre B., de Labriolle A., Grimard C., Zannad N., Babuty D. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008, 51:828-835.
88. Schaer B.A., Schneider C., Jick S.S., Conen D., Osswald S., Meier C.R. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med 2010, 152:78-84.
89. Holmes D.R., Reddy V.Y., Turi Z.G., Doshi S.K., Sievert H., Buchbinder M., et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009, 374:534-542.
90. Becker R.C., Meade T.W., Berger P.B., Ezekowitz M., O'Connor C.M., Vorchheimer D.A., et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(6 Suppl):776S-814S.
91. Haq S.A., Heitner J.F., Sacchi T.J., Brener S.J. Long-term effect of chronic oral anticoagulation with warfarin after acute myocardial infarction. Am J Med 2010, 123:250-258.
92. Massie B.M., Collins J.F., Ammon S.E., Armstrong P.W., Cleland J.G., Ezekowitz M., et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009, 119:1616-1624.
93. Pullicino P., Thompson J.L., Barton B., Levin B., Graham S., Freudenberger R.S., et al. Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design. J Card Fail 2006, 12:39-46.
94. Bonow R.O., Carabello B.A., Chatterjee K., De Leon A.C., Faxon D.P., Freed M.D., et al. focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2008 2008, 52:e1-e142.
95. Mok C.K., Boey J., Wang R., Chan T.K., Cheung K.L., Lee P.K., et al. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial. Circulation 1985, 72:1059-1063.
96. Little S.H., Massel D.R. Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev 2003, CD003464.
97. Di Tullio M.R., Sacco R.L., Sciacca R.R., Jin Z., Homma S. Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. J Am Coll Cardiol 2007, 49:797-802.
98. Overell J.R., Bone I., Lees K.R. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000, 55:1172-1179.
99. Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001;345:1740-1746.
100. Serena J., Marti-Fabregas J., Santamarina E., Rodriguez J.J., Perez-Ayuso M.J., Masjuan J., et al. Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study. Stroke 2008, 39:3131-3136.
101. Homma S., Sacco R.L., Di Tullio M.R., Sciacca R.R., Mohr J.P. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002, 105:2625-2631.
102. Furlan A.J., Reisman M., Massaro J., Mauri L., Adams H., Albers G.W., et al. Study Design of the CLOSURE I Trial: A Prospective, Multicenter, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex Septal Closure System Versus Best Medical Therapy in Patients With Stroke or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale. Stroke 2010, 41:2872-2883.
103. O'Gara P.T., Messe S.R., Tuzcu E.M., Catha G., Ring J.C. Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trials: a science advisory from the American Heart Association/American Stroke Association and the American College of Cardiology Foundation. Circulation 2009, 119:2743-2747. American Heart Association.
104. Georgiadis D., Arnold M., von Buedingen H.C., Valko P., Sarikaya H., Rousson V., et al. Aspirin vs anticoagulation in carotid artery dissection: a study of 298 patients. Neurology 2009, 72:1810-1815.
105. Lyrer P., Engelter S. Antithrombotic drugs for carotid artery dissection. Stroke 2004, 35:613-614.
106. Menon R., Kerry S., Norris J.W., Markus H.S. Treatment of cervical artery dissection: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2008, 79:1122-1127.
107. Pham M.H., Rahme R.J., Arnaout O., Hurley M.C., Bernstein R.A., Batjer H.H., et al. Endovascular stenting of extracranial carotid and vertebral artery dissections: a systematic review of the literature. Neurosurgery 2011, 68:856-866.
108. Ridker P.M., Goldhaber S.Z., Danielson E., Rosenberg Y., Eby C.S., Deitcher S.R., et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003, 348:1425-1434.
109. Levine S.R., Brey R.L., Tilley B.C., Thompson J.L., Sacco R.L., Sciacca R.R., et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004, 291:576-584.
110. Kronzon I., Tunick P.A. Aortic atherosclerotic disease and stroke. Circulation 2006, 114:63-75.
111. Di Tullio M.R., Russo C., Jin Z., Sacco R.L., Mohr J.P., Homma S., et al. Aortic arch plaques and risk of recurrent stroke and death. Circulation 2009, 119:2376-2382.
112. Tunick P.A., Nayar A.C., Goodkin G.M., Mirchandani S., Francescone S., Rosenzweig B.P., et al. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol 2002, 90:1320-1325.
113. Macleod M.R., Amarenco P., Davis S.M., Donnan G.A. Atheroma of the aortic arch: an important and poorly recognised factor in the aetiology of stroke. Lancet Neurol 2004, 3:408-414.
114. Hiratzka L.F., Bakris G.L., Beckman J.A., Bersin R.M., Carr V.F., Casey D.E., et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. J Am Coll Cardiol 2010, 55:e27-e129.
115. Stam J, de Bruijn SF, deVeber G. Anticoagulation for cerebral sinus thrombosis. Cochrane Database of Systematic Reviews 2002;Issue 4. Art. No.: CD002005.
116. Kearon C., Kahn S.R., Agnelli G., Goldhaber S., Raskob G.E., Comerota A.J., et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(6 Suppl):454S-545S.
117. Einhaupl K., Stam J., Bousser M.G., De Bruijn S.F., Ferro J.M., Martinelli I., et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol 2010, 17:1229-1235.
118. Saposnik G., Barinagarrementeria F., Brown R.D., Bushnell C.D., Cucchiara B., Cushman M., deVeber G., Ferro J.M., Tsai F.Y. American Heart Association Stroke Council and the Council on Epidemiology and Prevention. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011, 42:1158-1192.